Navigation Links
Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
Date:12/13/2011

New Rochelle, NY, December 12, 2011A recent article in the New England Journal of Medicine showed that Factor IX gene therapy in patients with hemophilia B was able to convert severe hemophilia to moderate or even mild disease. In a timely commentary, Thierry VandenDriessche, PhD, Methods Editor for Human Gene Therapy and Human Gene Therapy Methods says that this clinical trial represents an important milestone and "demonstrates unequivocally that gene therapy can result in a sustained therapeutic effect in hemophilia B patients." Read the commentary and listen to the accompanying podcast from Human Gene Therapy. Human Gene Therapy and HGT Methods are peer-reviewed journals published by Mary Ann Liebert, Inc..

The clinical trial reported in NEJM "builds on prior work and on encouraging pre-clinical data in non-human primates," states VandenDriessche and coauthor of the commentary with Marinee Chuah, PhD, Department of Gene Therapy & Regenerative Medicine, Free University of Brussels and the Center for Molecular and Vascular Biology, University of Leuven, Belgium. It demonstrated that injection of an adeno-associated virus (AAV) vector carrying the gene for the clotting factor FIX into patients with severe hemophilia B led to efficient delivery of the gene into liver cells and sufficient production of the FIX protein to transform the disease from severe to a moderate or mild form of hemophilia, although it does not represent a cure. This effect has been stable and has eliminated or substantially reduced the need for the patients to receive standard protein replacement, which is cumbersome and expensive. Substantial improvements in vector technology set the stage for this success; these included a self-complementary genome to increase efficiency pioneered by R. Jude Samulski, PhD, Director, Gene Therapy Center, University of North Carolina at Chapel Hill, and the use of a novel AAV capsid from a natural rhesus monkey isolate called AAV8, which was discovered and developed by James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy and Human Gene Therapy Methods, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Recently published articles in Human Gene Therapy document the development and optimization of the AAV vectors used to deliver the FIX gene in this clinical trial. Two key papers are:

"The successful treatment of patients with hemophilia B with gene therapy is a landmark event representing the culmination of over 20 years of work by many laboratories," says James M. Wilson, MD, PhD. "We are delighted that Human Gene Therapy was a venue for publishing critical aspects of the development of this product."


'/>"/>

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2165
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. BUSM faculty author commentary on the global challenges of emerging viral infections
2. Expert commentary on Earth Days 40th anniversary
3. SectorWatch.biz Issues Commentary for Investors of Homeland Defense Companies FOUR, MAGS, NSSC, PNTR, BCO, and CKP
4. New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy
5. American Migraine Foundation launches new podcast series
6. New American Chemical Society podcast: Tiny sea creature and a new medical adhesive
7. LSUHSC conducts landmark study of mid, long-term health effects of oil exposure
8. Landmark report reveals immense burden of osteoporotic fractures in Europe
9. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
10. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
11. Fruit flies use horizontal landmarks for altitude control, says Caltech research team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics ... secured $2M in funding from an impressive group of investors, including Rev1 Ventures, ... Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering that ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... ... Any expert in stem cell research or stem cell medicine knows well the ... Despite their essential roles in human health and regenerative medicine, adult tissue stem ... this purpose also tag other, more abundant, non-stem tissue cells ( See 2017 Cell ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO ... mobile responsive, the new website makes it easy to navigate through the site ... can now find detailed product information, educational industry content and visit the company’s ...
Breaking Biology Technology: